RxDoctor Payments Data

Aarushi Suneja, MD

Neurology · Cleveland, OHNPI 1033573944

Payments from drug & device makers

$328,921in general payments, 2019–2025

Across 415 payments — averaging $792.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$155K
  • AbbVie$128K
  • H. Lundbeck A S$42K
  • Lundbeck LLC$2K
  • Teva Pharmaceuticals USA, Inc.$231
  • Lilly USA, LLC$154
  • plus $474 from 5 others

What the payments were for

  • Consulting fees$44,67317%
  • Speaking & faculty fees$117,40644%
  • Grants$80,00030%
  • Travel & lodging$18,5017%
  • Food & beverage$8,7383%
  • Education$810%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$328,921 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$29,104
Medicare patients
153
Services billed
229

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate32$44,086
UbrelvyUbrogepant30$39,471
QuliptaAtogepant29$30,357
Emgality PenGalcanezumab-Gnlm17$17,347
Sumatriptan Succinate29$3,486
Oxcarbazepine63$2,816
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$2,754
Gabapentin136$1,533
Pregabalin28$1,150
Lacosamide13$637
Methocarbamol57$489
Baclofen44$407
Lamotrigine27$340
Memantine Hcl35$331
Topiramate36$320

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$128,251$69,82759 claims
PfizerNurtec Odt$155,407$44,08632 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 702 neurology providers in Ohio.

Other neurology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →